Ansell, CSL and ResMed: 3 stocks to buy now

According to a report on, newly installed healthcare analysts at stock broker CLSA Zara Lyons and David Stanton have initiated coverage of the following three high quality healthcare stocks with ‘buy’ recommendations.

1. Ansell (ASX: ANN) manufacturers a range of gloves and condoms for the industrial, medical, specialty and retail sectors globally. The firm has a market capitalisation of $2.5 billion and has seen its shares rally nearly 23% in the past 12 months, which is slightly more than the 21.7% rise in the S&P/ASX 200 Index (Index: ^AXJO) (ASX: XJO). With leverage to a growing global economy – particularly manufacturing – Ansell’s long-term outlook for earnings growth looks solid.

2. CSL (ASX: CSL) is a vertically integrated biotech company. The firm conducts research, development, manufacturing, marketing and distribution of its products with a focus on treatments derived from human blood plasma. With global operations and a market capitalisation of $33.4 billion, the firm is well positioned to continue to grow and expand both its product offer and customer reach. CSL’s shares have surged 48% in the past year however Lyons and Stanton obviously see further upside potential.

3. ResMed (ASX: RMD) is a leading provider of medical equipment for treating, diagnosing and managing breathing issues, with a particular focus on obstructive sleep apnea (OSA). ResMed has a market capitalisation of $7.3 billion but despite its market leading status it still only has a relatively small share of the OSA market, which means there is still enormous growth potential. The shares are up over 33% since October last year however the size of the undiagnosed OSA market means ResMed is still on an exciting growth trajectory.

Foolish takeaway

Warren Buffett learnt decades ago that buying great companies at conservative prices is a winning strategy. Ansell, CSL and ResMed all have the attributes of great companies including quality management, long runways of future growth and certain barriers to entry which help keep competitors away.

Is your portfolio in need of a health check? Receive The Motley Fool's favourite income idea for 2013-2014 in our brand-new, FREE research report, including a full investment analysis! Simply click here for your FREE copy of "The Motley Fool's Top Dividend Stock for 2013-2014."

Motley Fool contributor Tim McArthur does not own shares in any of the companies mentioned in this article.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.